SUNNYVALE, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced that in connection with its previously announced public offering of 6,808,154 shares of its common stock, the underwriters fully exercised and closed on their option to purchase up to an additional 1,021,223 shares of common stock from certain selling securityholders at the public offering price of $39.00 per share, less the underwriting discounts and commissions. Silk Road Medical did not receive proceeds from the sale of its common stock by the selling securityholders.
​
J.P. Morgan and BofA Securities acted as joint book-running managers of the offering. Citigroup also acted as book-running manager. Stifel acted as co-manager.

Read More: https://www.globenewswire.com/news-release/2020/05/20/2036678/0/en/Silk-Road-Medical-Announces-Full-Exercise-and-Closing-of-Over-Allotment-Option.html

As I wrote in Issue 052, Hinge CEO and co-founder Daniel Perez predicted that during the coronavirus pandemic:

“Health plans and employers want a trusted solution in times of uncertainty. My prediction (from the eye of the storm) is that over the next six months we’re going to see the most trusted solutions (Livongo, Hinge Health, Teladoc) continue to outperform their peers, and gain even more market share.”

I was impressed by his sleight-of-hand — sandwiching his startup in between two of the only publicly traded digital health companies! — but it did get me thinking a bit more about Hinge’s competition.

There’s a strong likelihood that by the end of 2020, Hinge’s main competitors will be Livongo and Omada Health.

Read More: https://exitsandoutcomes.com/why-omada-health-should-buy-physera-and-other-msk-ma-digital-health-predictions/

SUNNYVALE, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the closing of an underwritten public offering of 6,808,154 shares of its common stock at a public offering price of $39.00 per share. 1,923,076 shares in the offering were offered for sale by Silk Road Medical, and 4,885,078 million shares were offered for sale by certain selling securityholders. Gross proceeds from the offering to Silk Road Medical were approximately $75 million.  The selling stockholders granted the underwriters a 30-day option to purchase up to an additional 1,021,223 shares of common stock at the public offering price, less the underwriting discounts and commissions. Silk Road Medical did not receive proceeds from the sale of its common stock by the selling securityholders.

J.P. Morgan and BofA Securities acted as joint book-running managers of the offering. Citigroup also acted as book-running manager. Stifel acted as co-manager.

Read More: ​https://www.globenewswire.com/news-release/2020/05/08/2030564/0/en/Silk-Road-Medical-Announces-Closing-of-Follow-on-Public-Offering.html

SAN JOSE, Calif., May 7, 2020 /PRNewswire/ -- Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced along with the U.S. Department of Health and Human Services (HHS) and in collaboration with the New York State Department of Health that they have deployed 50 Tablo™ Hemodialysis Systems to hospitals in New York City and Long Island.  The first five locations include Long Island Jewish Medical Center, North Shore University Hospital, Mount Sinai South Nassau, Staten Island University Hospital – North, and Brooklyn Hospital Center - Downtown Campus.  Five additional hospitals in NYC are also expected to receive Tablo systems in the near term as part of this deployment.

This is the first time HHS has sent Tablos to emergency locations since signing a multiyear contract with Outset in October.  The agency's stated mission for this unique, mobile technology is to serve dialysis patients in communities hit by natural disasters.

Read More: https://www.prnewswire.com/news-releases/fifty-tablo-mobile-dialysis-systems-deployed-to-new-york-hospitals-by-us-department-of-health-and-human-services-for-covid-19-disaster-recovery-response-301055432.html?tc=eml_cleartime

SUNNYVALE, Calif. , May 05, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the pricing of an underwritten public offering of 6,808,154 shares of its common stock at a public offering price of $39.00 per share, before deducting underwriting discounts and commissions. 1,923,076 shares in the offering are being offered for sale by Silk Road Medical, and 4,885,078 shares are being offered for sale by certain selling securityholders. In addition, the selling securityholders have granted the underwriters a 30-day option to purchase up to an additional 1,021,223 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering to Silk Road are expected to be approximately $75 million. Silk Road Medical will not receive proceeds from the sale of its common stock by selling securityholders. The offering is expected to close on May 8, 2020, subject to the satisfaction of customary closing conditions.

Read More: https://www.globenewswire.com/news-release/2020/05/06/2028107/0/en/Silk-Road-Medical-Announces-Pricing-of-Upsized-Public-Offering.html#:~:text=(Nasdaq%3A%20SILK)%20(%E2%80%9C,before%20deducting%20underwriting%20discounts%20and

SUNNYVALE, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, announced today the commencement of a proposed underwritten public offering of $100 million of shares of its common stock. $75 million of the shares in the offering are being offered for sale by Silk Road Medical and $25 million of the shares are being offered for sale by certain selling securityholders. In addition, the selling securityholders expect to grant the underwriters a 30-day option to purchase up to an additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Silk Road Medical intends to use the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by Silk Road Medical, to expand its sales force and operations, increase research and development activities, conduct or sponsor clinical studies and trials, lease new facilities, expand internationally, and to provide for working capital and other general corporate purposes. Silk Road Medical may use a portion of the net proceeds to repay debt or acquire complimentary products, technologies, intellectual property or businesses; however, Silk Road Medical currently does not have any agreements or commitments to complete any such transactions and is not involved in negotiations regarding such transactions.
​
Read More: https://www.globenewswire.com/news-release/2020/05/05/2027940/0/en/Silk-Road-Medical-Announces-Proposed-Public-Offering-of-Common-Stock.html